rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Glenn Sblendorio

Director

Company insider

Files Form 4 as: Director, 4D Molecular Therapeutics; Director, Amicus Therapeutics; Director, Mineralys Therapeutics; Director, Intercept Pharmaceuticals; Chief Executive Officer, IVERIC bio; President & CFO, Medicines Co /de.

Every Form 4 they filed

In numbers

Trades disclosed
407
Buys
6
Sells
72
Bought
$432K
Sold
$23.4M
Companies
6
Companies where not an officer
4
First trade
3 Mar 2006
Last trade
17 Jun 2026
Last filed
18 Jun 2026

Companies traded

Where they are an officer
IVERIC bioDirector, Officer · last 11 Jul 20234 buys · 26 sells
Medicines Co /deDirector, Officer · last 3 Sep 20150 buys · 42 sells
Everywhere else they filed: board seats, 10% stakes, other companies
FDMT 4D Molecular TherapeuticsDirector · Biotechnology · last 17 Jun 20260 buys · 0 sells
Amicus TherapeuticsDirector · Biotechnology · last 27 Apr 20262 buys · 4 sells
MLYS Mineralys TherapeuticsDirector · Biotechnology · last 19 Feb 20260 buys · 0 sells
Intercept PharmaceuticalsDirector · last 8 Nov 20230 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
17 Jun 2026filed 18 Jun 2026FDMT 4D Molecular Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—50,000 at $0.00filing
17 Jun 2026filed 18 Jun 2026FDMT 4D Molecular Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—50,000 at $0.00filing
27 Apr 2026filed 27 Apr 2026Amicus TherapeuticsBiotechnologySEC FORM 4 Code D$2.1M142,564 at $14.50filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—74,872filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—20,000filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—16,236filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—20,000filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—16,236filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—19,473filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—18,574filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—36,111filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—45,423filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—30,474filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—42,467filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—74,872filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—19,473filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—18,574filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—36,111filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—45,423filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—30,474filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed78

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.